Jump to main content
Jump to site search

Issue 6, 2018
Previous Article Next Article

Synthetic and immunological studies on trimeric MUC1 immunodominant motif antigen-based anti-cancer vaccine candidates

Author affiliations

Abstract

Therapeutic vaccines have been regarded as a very promising treatment modality against cancer. Tumor-associated MUC1 is a promising antigen for the design of antitumor vaccines. However, body's immune tolerance and low immunogenicity of MUC1 glycopeptides limited their use as effective antigen epitopes of therapeutic vaccines. To solve this problem, we chose the immune dominant region of MUC1 VNTRs. We designed and synthesized its linear trivalent glycopeptide fragments and coupled the fragments with BSA. Immunological evaluation indicated that the antibodies induced by glycosylated MUC1 based vaccine 11 had a stronger binding than non-glycosylated 10. The novel constructed antigen epitopes have the potential to overcome the weak immunogenicity of natural MUC1 glycopeptides and deserve further research.

Graphical abstract: Synthetic and immunological studies on trimeric MUC1 immunodominant motif antigen-based anti-cancer vaccine candidates

Back to tab navigation

Supplementary files

Publication details

The article was received on 02 Dec 2017, accepted on 10 Jan 2018 and first published on 10 Jan 2018


Article type: Paper
DOI: 10.1039/C7OB02976D
Citation: Org. Biomol. Chem., 2018,16, 993-999
  •   Request permissions

    Synthetic and immunological studies on trimeric MUC1 immunodominant motif antigen-based anti-cancer vaccine candidates

    M. Li, F. Yu, C. Yao, P. G. Wang, Y. Liu and W. Zhao, Org. Biomol. Chem., 2018, 16, 993
    DOI: 10.1039/C7OB02976D

Search articles by author

Spotlight

Advertisements